28th Nov 2017 10:24
Stock Exchange Announcement
For immediate release | 28th November 2017 |
|
|
Hikma Pharmaceuticals Public Limited Company
(the "Issuer")
Re: Additional Guarantors of U.S.$500,000,000 4.250 per cent. Guaranteed Notes due 2020
(ISIN: XS1213834978)
(the "Notes")
guaranteed by each of
Arab Pharmaceutical Manufacturing PSC
Eurohealth (USA), Inc.
Hikma Farmacêutica (Portugal) S.A.
Hikma Pharmaceuticals LLC and
West-Ward Pharmaceutical Corp.
(the "Initial Guarantors")
The Issuer refers to (i) the terms and conditions of the Notes (the "Conditions") set out in the prospectus dated 8 April 2015 relating to the Notes and (ii) a deed of guarantee dated 10 April 2015 between the Issuer and the Initial Guarantors in favour of the Holders and the Relevant Account Holders (each as defined therein) (the "Deed of Guarantee").
Capitalised terms used in this Notice and not defined herein shall have the meanings as set out in the Conditions and the Deed of Guarantee.
NOTICE IS HEREBY GIVEN that, pursuant to and in compliance with the provisions of Condition 5.7 (Guarantor Group) and the Deed of Guarantee:
a) as of 21 August 2017, West-Ward Pharmaceuticals International Limited has, pursuant to an accession deed of guarantee dated 21 August 2017 and an accession deed of covenant dated 21 August 2017, become a Guarantor;
b) as of 29 April 2016, Roxane Laboratories, Inc. has, pursuant to an accession deed of guarantee dated 29 April 2016 and an accession deed of covenant dated 29 April 2016, become a Guarantor; and
c) as of 29 April 2016, West-Ward Columbus Inc. has, pursuant to an accession deed of guarantee dated 29 April 2016 and an accession deed of covenant dated 29 April 2016, become a Guarantor.
West-Ward Pharmaceuticals International Limited, Roxane Laboratories, Inc. and West-Ward Columbus Inc. are together "the Additional Guarantors".
Each Additional Guarantor has agreed to:
a) perform and observe all obligations expressed to be undertaken by a Guarantor under the Conditions, the Deed of Guarantee, a deed of covenant between the Issuer and the Initial Guarantors dated 10 April 2015 (the "Deed of Covenant") and a fiscal agency agreement between, among others, the Issuer, the Initial Guarantors and Citibank, N.A., London Branch dated 10 April 2015 (the "Fiscal Agency Agreement"), and each agrees that it shall be bound by the Conditions, the Deed of Guarantee, the Deed of Covenant and the Fiscal Agency Agreement in all respect as if it had been an original party thereto; and
b) jointly and severally with all the Initial Guarantors, unconditionally and irrevocably guarantee the payment of all sums expressed to be payable by the Issuer in respect of the Notes to the Holders and the Relevant Account Holders.
The following is the relevant information for the Additional Guarantors:
Registered name: | West-Ward Pharmaceuticals International Limited |
Place of incorporation: | England and Wales |
Date of incorporation: | 23rd June 2011 |
Registered number: | 07680243 |
Registered address: | 1 New Burlington Place, London, W1S 2HR |
Ownership: | The Additional Guarantor is a wholly owned subsidiary of the Issuer. |
Registered name: | West-Ward Columbus Inc. |
Place of incorporation: | Registered in the state of Delaware |
Date of incorporation: | 27th November 1978 |
Registered number: | 863458 |
Registered address: | 1809 Wilson RoadColumbusOH 43228United States |
Ownership: | The Additional Guarantor is a wholly owned subsidiary of the Issuer. |
Registered name: | Roxane Laboratories, Inc. |
Place of incorporation: | Registered in the state of Nevada |
Date of incorporation: | 14 February 2005 |
Registered number: | E0034412005-8 |
Registered address: | 1809 Wilson RoadColumbus OH 43228United States |
Ownership: | The Additional Guarantor is a wholly owned subsidiary of the Issuer. |
Enquiries:
For enquiries or further information please contact: Peter Speirs Company Secretary Hikma Pharmaceuticals PLC E-mail: [email protected]
|
This announcement has been issued through the Companies Announcement Service of
The Irish Stock Exchange
Related Shares:
Hikma Pharmaceuticals